KRAS mutations in lung adenocarcinoma: Molecular and epidemiological characteristics, methods for detection, and therapeutic strategy perspectives

Current Molecular Medicine

Volumn 15, Issue 5, 2015, Pages 418-432

  Guibert, N ^a   Ilie, M ^a,b   Long, E ^a,b   Hofman, V ^a,b   Bouhlel, L ^a,b   Brest, P ^a   Mograbi, B ^a   Marquette, C H ^a,b   Didier, A ^c   Mazieres J ^c   Hofman, P ^a,b  

^a UNIVERSITY OF NICE SOPHIA ANTIPOLIS   (France)

^b PASTEUR HOSPITAL   (France)

^c SERVICE DE PNEUMOLOGIE   (France)

Author keywords

Clinical trials; Epidemiology; KRAS mutation; Lung adenocarcinoma; Personalized medicine; Prognosis; Targeted therapy

Indexed keywords

ABEMACICLIB; ALPELISIB; BORTEZOMIB; COBIMETINIB; DOCETAXEL; ERLOTINIB; FASUDIL; K RAS PROTEIN; RETASPIMYCIN; SELUMETINIB; SORAFENIB; TRAMETINIB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; KRAS PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PROTEIN P21; TUMOR MARKER;

ARTICLE; BRONCHUS BIOPSY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CIRCULATING TUMOR CELL; CYTOLOGY; ETHNICITY; FINE NEEDLE ASPIRATION BIOPSY; GENE EXPRESSION; GENE MUTATION; HISTOLOGY; IMMUNOTHERAPY; LUNG ADENOCARCINOMA; LUNG LAVAGE; META ANALYSIS (TOPIC); OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLEURA FLUID; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOKING; TISSUE SECTION; TREATMENT RESPONSE; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LUNG NEOPLASMS; METABOLISM; MOLECULAR DIAGNOSIS; MOLECULARLY TARGETED THERAPY; MUTATION; PROCEDURES; PROGNOSIS; RISK FACTOR;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MOLECULAR DIAGNOSTIC TECHNIQUES; MOLECULAR TARGETED THERAPY; MUTATION; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK FACTORS;

EID: 84936887587     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/1566524015666150505161412     Document Type: Article

References (127)

1. [1] Machtay M, Duan F, Siegel BA, et al. Prediction of Survival by [18F]Fluorodeoxyglucose Positron Emission Tomography in Patients With Locally Advanced Non-Small-Cell Lung Cancer Undergoing Definitive Chemoradiation Therapy: Results of the ACRIN 6668/RTOG 023f Trial. J Clin Oncol 2013; 31: 3823-3830.
2. [2] Weinstein IB. Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science 2002;297: 63-64.
3. [3] Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-246.
4. [4] Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12: 735-742.
5. [5] Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368: 2385-2394.
6. [6] Mitin N, Rossman KL, Der CJ. Signaling interplay in Ras superfamily function. Curr Biol 2005; 15: R563-574.
7. [7] Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 2008; 9: 517-531.
8. [8] Riely GJ, Kris MG, Rosenbaum D, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 2008; 14: 5731-5734.
9. [9] Porta M, Crous-Bou M, Wark PA, et al. Cigarette smoking and K-ras mutations in pancreas, lung and colorectal adenocarcinomas: etiopathogenic similarities, differences and paradoxes. Mutat Res 2009; 682: 83-93.
10. [10] Fiala O, Pesek M, Finek J, et al. The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Cancer Genet 2013; 206: 26-31.
11. [11] Cserepes M, Ostoros G, Lohinai Z, et al. Subtype-specific KRAS mutations in advanced lung adenocarcinoma: A retrospective study of patients treated with platinum-based chemotherapy. Eur J Cancer 2014; 50: 1819-1828.
12. [12] Phillips DH. Smoking-related DNA and protein adducts in human tissues. Carcinogenesis 2002; 23: 1979-2004.
13. [13] Ihle NT, Byers LA, Kim ES, et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst 2012; 104: 228-239.
14. [14] Mascaux C, Iannino N, Martin B et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2005; 92: 131-139.
15. [15] Villaruz LC, Socinski MA, Cunningham DE, et al. The prognostic and predictive value of KRAS oncogene substitutions in lung adenocarcinoma. Cancer 2013; 119: 2268-2274.
16. [16] Graziano SL, Gamble GP, Newman NB, et al. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. J Clin Oncol 1999; 17: 668-675.
17. [17] Ahrendt SA, Decker PA, Alawi EA, et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 2001; 92: 1525-1530.
18. [18] Dearden S, Stevens J, Wu YL, Blowers D. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol 2013; 24: 2371-2376.
19. [19] Mao C, Qiu LX, Liao RY, et al. 2010. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies. Lung Cancer 2010; 69: 272-278.
20. [20] Kosaka T, Yatabe, Y, Onozato R, Kuwano H, Mitsudomi T. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J Thorac Oncol 2009; 4: 22-29.
21. [21] Couraud S, Zalcman G, Milleron B, Morin F, Souquet PJ. Lung cancer in never smokers-a review. Eur J Cancer 2012; 48: 1299-1311.
22. [22] Hunt JD, Strimas A, Martin JE, et al. Differences in KRAS mutation spectrum in lung cancer cases between African Americans and Caucasians after occupational or environmental exposure to known carcinogens. Cancer Epidemiol Biomarkers Prev 2002; 11: 1405-1412.
23. [23] Bauml J, Mick R, Zhang Y, et al. Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: do disparities exist? Lung Cancer 2013; 81: 347-353.
24. [24] Slebos RJ, Kibbelaar RE, Dalesio O, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990; 323: 561-565.
25. [25] Ohtaki Y, Shimizu K, Kakegawa S, et al. Postrecurrence survival of surgically resected pulmonary adenocarcinoma patients according to EGFR and KRAS mutation status. Mol Clin Oncol 2014; 2: 187-196.
26. [26] Guan J, Zhong W, An S, et al. KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapy. Ann Surg Oncol 2013; 20:1381-1388.
27. [27] Shepherd FA, Domerg C, Hainaut P, et al. Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol 2013; 31: 2173-2181.
28. [28] Broermann P, Junker K, Brandt BH, et al. Trimodality treatment in Stage III nonsmall cell lung carcinoma: prrognostic impact of K-ras mutations after neoadjuvant therapy. Cancer 2002; 94: 2055-2062.
29. [29] Rodenhuis S, Boerrigter L, Top B, et al. Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study. J Clin Oncol 1997; 15: 285-291.
30. [30] Schiller JH, Adak S, Feins RH, et al. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy. J Clin Oncol 2001; 19: 448-457.
31. [31] Nygaard AD, Garm Spindler KL, Pallisgaard N, Andersen RF, Jakobsen A. The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer. Lung Cancer 2013; 79: 312-317.
32. [32] Cuffe S, Bourredjem A, Graziano S, et al. A pooled exploratory analysis of the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy in node-negative non-small cell lung cancer. J Thorac Oncol 2012; 7: 963-972.
33. [33] Metro G, Chiari R, Bennati C, et al. Clinical Outcome With Platinum-Based Chemotherapy in Patients With Advanced Nonsquamous EGFR Wild-Type Non-Small-Cell Lung Cancer Segregated According to KRAS Mutation Status. Clin Lung Cancer 2014; 15: 86-92.
34. [34] Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352: 2589-2597.
35. [35] Moran DM, Trusk PB, Pry KJ, Paz K, Sidransky D, Bacus SS. KRAS mutation status is associated with enhanced dependency on folate metabolism pathways in Non Small Cell Lung Cancer cells. Mol Cancer Ther 2014; 13: 1611-1624.
36. [36] Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005; 2: e17.
37. [37] Massarelli E, Varella-Garcia M, Tang X, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res, 2007; 13: 2890-2896.
38. [38] Brugger W, Triller N, Blasinska-Morawiec M, al. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol 2011; 29: 4113-4120.
39. [39] Linardou H, Dahabreh IJ, Kanaloupiti D, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008; 9: 962-972.
40. [40] Raponi M, Winkler H, Dracopoli NC. KRAS mutations predict response to EGFR inhibitors. Curr Opin Pharmacol 2008; 8: 413-418.
41. [41] Mao C, Qiu LX, Liao RY, et al. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies. Lung Cancer 2010; 69: 272-278.
42. [42] Jackman DM, Miller VA, Cioffredi LA, et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 2009; 15: 5267-5273.
43. [43] Douillard JY, Shepherd FA, Hirsh V, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2010; 28: 744-752.
44. [44] Kim ST, Sung JS, Jo UH, Park KH, Shin SW, Kim YH. Can mutations of EGFR and KRAS in serum be predictive and prognostic markers in patients with advanced non-small cell lung cancer (NSCLC)? Med Oncol 2013; 30: 328.
45. [45] Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011; 29: 2866-2874.
46. [46] Khambata-Ford S, Harbison CT, Hart LL, et al. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 918-927.
47. [47] Lurkin I, Stoehr R, Hurst CD, et al. Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes. PLoS One 2010; 5:e8802.
48. [48] Heideman DAM, Thunnissen FB, Doeleman M, et al. A panel of high resolution melting (HRM) technology-based assays with direct sequencing possibility for effective mutation screening of EGFR and K-ras genes. Cell Oncol 2009; 31: 329-333.
49. [49] Adams JA, Post KM, Bilbo SA, et al. Performance evaluation comparison of 3 commercially available PCR-based KRAS mutation testing platforms. Appl. Immunohistochem. Mol Morphol 2014; 22: 231-235.
50. [50] Scarpa A, Sikora K, Fassan M, et al. Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel. PLoS One 2013; 8: e80478.
51. [51] Chowdhuri SR, Xi L, Pham THT, et al. EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection. Mod Pathol 2012; 25: 548-555.
52. [52] Jurado J, Saqi A, Maxfield R, et al. The Efficacy of EBUS-Guided Transbronchial Needle Aspiration for Molecular Testing in Lung Adenocarcinoma. Ann Thorac Surg 2013; 96: 1196-1202.
53. [53] Boulanger S, Delattre C, Descarpentries C, et al. [Feasibility of assessing EGFR mutation and others using samples obtained by EBUS transbronchial needle aspiration]. Rev Mal Respir 2013; 30: 351-356.
54. [54] Nakajima T, Yasufuku K, Nakagawara A, Kimura H, Yoshino I. Multigene mutation analysis of metastatic lymph nodes in non-small cell lung cancer diagnosed by endobronchial ultrasound-guided transbronchial needle aspiration. Chest 2011; 140: 1319-1324.
55. [55] Stigt JA, 'tHart, NA, Knol AJ, Uil SM, Groen HJM. Pyrosequencing analysis of EGFR and KRAS mutations in EUS and EBUS-derived cytologic samples of adenocarcinomas of the lung. J Thorac Oncol 2013; 8: 1012-1018.
56. [56] Ferretti G, Curigliano G, Pastorino U, et al. Detection by denaturant gradient gel electrophoresis of tumor-specific mutations in biopsies and relative bronchoalveolar lavage fluid from resectable non-small cell lung cancer. Clin Cancer Res 2000; 6: 2393-2400.
57. [57] Yamaguchi F, Kugawa S, Tateno H, Kokubu F, Fukuchi K. Analysis of EGFR, KRAS and P53 mutations in lung cancer using cells in the curette lavage fluid obtained by bronchoscopy. Lung Cancer 2012; 78: 201-206.
58. [58] Che J, Mach AJ, Go DE, et al. Microfluidic purification and concentration of malignant pleural effusions for improved molecular and cytomorphological diagnostics. PLoS One 2013; 8: e78194.
59. [59] Yang MJ, Chiu HH, Wang HM, et al. Enhancing detection of circulating tumor cells with activating KRAS oncogene in patients with colorectal cancer by weighted chemiluminescent membrane array method. Ann Surg Oncol 2010; 17: 624-633.
60. [60] Chen YF, Wang JY, Wu CH, Chen FM, Cheng TL, Lin SR. Detection of circulating cancer cells with K-ras oncogene using membrane array. Cancer Lett 2005; 229: 115-122.
61. [61] Wang S, An T, Wang J, et al. Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced non-small cell lung cancer. Clin Cancer Res 2010; 16: 1324-1330.
62. [62] Zhang H, Liu D, Li S, et al. Comparison of EGFR Signaling Pathway Somatic DNA Mutations Derived From Peripheral Blood and Corresponding Tumor Tissue of Patients with Advanced Non-Small-Cell Lung Cancer Using Liquidchip Technology. J Mol Diagn 2013; 15: 819-826.
63. [63] Mazieres J, Pradines A, Favre G. Perspectives on farnesyl transferase inhibitors in cancer therapy. Cancer Lett 2004; 206: 159-167.
64. [64] Adjei AA, Mauer A, Bruzek L, et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21: 1760-1766.
65. [65] Johnson BE, Heymach JV. Farnesyl transferase inhibitors for patients with lung cancer. Clin. Cancer Res 2004; 10: 4254s-4257s.
66. [66] Riely GJ, Johnson ML, Medina C, et al. A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations. J Thorac Oncol 2011; 6: 1435-1437.
67. [67] Sebti SM, Hamilton AD. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene 2000; 19: 6584-6593.
68. [68] Lobell RB, Liu D, Buser CA, et al. Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I. Mol Cancer Ther 2002; 1: 747-758.
69. [69] Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 2013; 503: 548-551.
70. [70] Bollag G, Zhang C. Drug discovery: Pocket of opportunity, Nature 2013; 503: 475-476.
71. [71] Lim SM, Westover KD, Ficarro SB, et al. Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor. Angew Chem Int Ed Engl 2014; 53: 199-204.
72. [72] Leshchiner ES, Parkhitko A, Bird GH, et al. Direct inhibition of oncogenic KRAS by hydrocarbon-stapled SOS1 helices. Proc Natl Acad Sci USA 2015; 112: 1761-1766.
73. [73] Zimmermann G, Papke B, Ismail S, et al. Small molecule inhibition of the KRAS-PDE5 interaction impairs oncogenic KRAS signalling. Nature 2013; 497: 638-642.
74. [74] Van der Hoeven D, Cho K, Ma X, Chigurupati S, Parton RG, Hancock JF. Fendiline inhibits K-Ras plasma membrane localization and blocks K-Ras signal transmission. Mol Cell Biol 2013; 33: 237-251.
75. [75] Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial:personalizing therapy for lung cancer. Cancer Discov 2011; 1: 44-53.
76. [76] Dingemans AMC, Mellema WW, Groen HJM, et al. A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation. Clin Cancer Res 2013; 19: 743-751.
77. [77] Roberts PJ, Stinchcombe TE. KRAS mutation: should we test for it, and does it matter? J Clin Oncol 2013; 31: 1112-1121.
78. [78] Garon EB, Finn RS, Hosmer W, et al. Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines. Mol Cancer Ther 2010; 9: 1985-1994.
79. [79] Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008; 26: 2139-2146.
80. [80] Janne PA, Shaw AT, Pereira JR, et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 2013; 14: 38-47.
81. [81] Blumenschein GR, Smit EF, Planchard D, et al. A randomized phase 2 study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small cell lung cancer (NSCLC). Ann Oncol 2015; 26: 894-901.
82. [82] Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008; 455: 1069-1075.
83. [83] Chen Z, Cheng K, Walton Z, et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 2012; 483: 613-617.
84. [84] Yan C, Liu D, Li L, et al. Discovery and characterization of small molecules that target the GTPase Ral. Nature 2014; 515: 443-447.
85. [85] Hatzivassiliou G, Haling JR, Chen H, et al. Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature 2013; 501: 232-236.
86. [86] Engelman JA, Chen L, Tan X, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008; 14: 1351-1356.
87. [87] Castellano E, Sheridan C, Thin MZ, et al. Requirement for Interaction of PI3-Kinase p110a with RAS in Lung Tumor Maintenance. Cancer Cell 2013; 24: 617-630.
88. [88] Yuan TL, McCormick F. Killing Tumors by Keeping Ras and PI3' Kinase Apart. Cancer Cell 2013; 24: 562-563.
89. [89] Yoon YK, Kim HP, Han SW, et al. KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach. Mol Carcinog 2010; 49: 353-362.
90. [90] Simmons BH, Lee JH, Lalwani K, et al. Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras(G12D-LSL) mice. Cancer Chemother Pharmacol 2012; 70: 213-220.
91. [91] Holt SV, Logie A, Davies BR, et al. Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055). Cancer Res 2012; 72: 1804-1813.
92. [92] Hata AN, Yeo A, Faber AC, et al. Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung Cancers. Cancer Res 2014; 74: 3146-3156.
93. [93] Balbin OA, Prensner JR, Sahu A, et al. Reconstructing targetable pathways in lung cancer by integrating diverse omics data. Nat Commun 2013; 4: 2617.
94. [94] Rekhtman N, Ang DC, Riely GJ, Ladanyi M, Moreira AL. KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma. Mod Pathol 2013; 26: 1307-1319.
95. [95] Ji H, Houghton AM, Mariani TJ, et al. K-ras activation generates an inflammatory response in lung tumors. Oncogene 2006; 25: 2105-2112.
96. [96] Lastwika K, Wilson W, Dennis PA. PI3K/AKT/mTOR pathway activation drives expression of the immune inhibitory ligand PD-L1 in NSCLC. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013; 73(8 Suppl): Abstract nr 4981.
97. [97] Calles A, Liao X, Sholl LM, et al. Differential expression of LKB1, PD-L1, and PD-L2 in KRAS-mutant nonsmall cell lung cancer in never-smokers. J Clin Oncol 2014; 32(Suppl): abstract 8032.
98. [98] Yang CY, Lin MW, Chang YL, Wu CT, Yang PC. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur J Cancer 2014; 50: 1361-1369.
99. [99] Young A, Lou D, McCormick F. Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling. Cancer Discov 2013; 3: 112-123.
100. [100] Corcoran RB, Cheng KA, Hata AN, et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell 2013; 23: 121-128.
101. [101] Kumar MS, Hancock DC, Molina-Arcas M, et al. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell 2012; 149: 642-655.
102. [102] Barbacid M. Opening a new GATAway for treating KRAS-driven lung tumors. Cancer Cell 2012; 21: 598-600.
103. [103] Molina-Arcas M, Hancock DC, Sheridan C, Kumar MS, Downward J. Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer. Cancer Discov 2013; 3: 548-563.
104. [104] Chen R, Sweet-Cordero EA. Two is better than one: combining IGF1R and MEK blockade as a promising novel treatment strategy against KRAS-mutant lung cancer. Cancer Discov 2013; 3: 491-493.
105. [105] Sunaga N, Kaira K, Imai H, et al. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer. Oncogene 2013; 32: 4034-4042.
106. [106] Licciulli S, Avila JL, Hanlon L, et al. Notch1 Is Required for Kras-Induced Lung Adenocarcinoma and Controls Tumor Cell Survival via p53. Cancer Res 2013; 73: 5974-5984.
107. [107] Maraver A, Fernandez-Marcos PJ, Herranz D, et al. Therapeutic effect of y-secretase inhibition in KrasG12V-driven non-small cell lung carcinoma by derepression of DUSP1 and inhibition of ERK. Cancer Cell 2012; 22: 222-234.
108. [108] Saintigny P, Massarelli E, Lin S, et al. CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. Cancer Res 2013; 73: 571-582.
109. [109] Yuan A, Yang PC, Yu CJ, et al. Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer. Am J Respir Crit Care Med 2000; 162: 1957-1963.
110. [110] Palena C, Hamilton DH, Fernando RI. Influence of IL-8 on the epithelial-mesenchymal transition and the tumor microenvironment. Future Oncol 2012; 8: 713-722.
111. [111] Sunaga N, Imai H, Shimizu K, et al. Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer. Int J Cancer 2012; 130: 1733-1744.
112. [112] Zhu Z, Aref AR, Cohoon TJ, et al. Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discov 2014; 4: 452-465.
113. [113] McCleland ML, Adler AS, Deming L, et al. Lactate dehydrogenase B is required for the growth of KRAS-dependent lung adenocarcinomas. Clin Cancer Res 2013; 19: 773-784.
114. [114] Kasinski AL, Slack FJ. MiRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma. Cancer Res 2012; 72: 5576-5587.
115. [115] Shimamura T, Chen Z, Soucheray M, et al. Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. Clin Cancer Res 2013; 19: 6183-6192.
116. [116] Zhao P, Damerow MS, Stern P, et al. CD44 promotes Kras-dependent lung adenocarcinoma. Oncogene 2013; 32: 5186-5190.
117. [117] Tran PT, Shroff EH, Burns TF, et al. Twist1 suppresses senescence programs and thereby accelerates and maintains mutant Kras-induced lung tumorigenesis. PLoS Genet 2012; 8: e1002650.
118. [118] Hui L, Zhang S, Dong X, Tian D, Cui Z, Qiu X. Prognostic significance of twist and N-cadherin expression in NSCLC. PLoS One 2013; 8: e62171.
119. [119] Jiang W, Pang XG, Wang Q, Shen YX, Chen XK, Xi JJ. Prognostic role of Twist, Slug, and Foxc2 expression in stage I non-small-cell lung cancer after curative resection. Clin Lung Cancer 2013; 13: 280-287.
120. [120] Barbie DA, Tamayo P, Boehm JS, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009; 462: 108-112.
121. [121] Scholl C, Frohling S, Dunn IF, et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 2009; 137: 821-834.
122. [122] Puyol M, Martin A, Dubus P, et al. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 2010; 18: 63-73.
123. [123] Shapiro GI, Rosen LS, Tolcher AW, et al. A first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer. J Clin Oncol 31, 2013 (Suppl; abstr 2500).
124. [124] Wang I-C, Ustiyan V, Zhang Y, Cai Y, Kalin TV, Kalinichenko VV. Foxm1 transcription factor is required for the initiation of lung tumorigenesis by oncogenic Kras(G12D.). Oncogene 2014; 33: 5391-5396.
125. [125] Elsum IA, Yates LL, Pearson HB, et al. Scrib heterozygosity predisposes to lung cancer and cooperates with KRas hyperactivation to accelerate lung cancer progression in vivo. Oncogene 2014; 33: 5523-5533.
126. [126] Acquaviva J, Smith DL, Sang J, et al. Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib. Mol Cancer Ther 2012; 11: 2633-2643.
127. [127] Konstantinidou G, Ramadori G, Torti F, et al. RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas. Cancer Discov 2013; 3: 444-457.